3M VAC Veraflo Therapy applied on surgical patient

Start Smart with 3M™ Veraflo™ Therapy

Discover how negative pressure wound therapy with instillation is easier than ever to help promote healing for complex wounds.

REQUEST A DEMO

Introducing the new 3M™ Veraflo™ Therapy—an improved NPWTi-d redesigned for automated and efficient patient care.

  • We incorporated clinicians' feedback to create the new Veraflo Cleanse Choice Complete Dressing Kit. The kit includes fewer pieces, is easier to use and is more patient friendly than previous kits.

  • The Smart Instill Feature uses sophisticated software that automates many of the Veraflo Therapy steps and delivers an easier and less time-consuming interaction when initiating installation therapy.



What is Veraflo™ Therapy

A smart start to managing bioburden.

The number of microorganisms with which an object is contaminated is referred to as the bioburden.¹


Veraflo Therapy helps disrupt the bioburden cycle through repeated cleansing cycles.

  • Hands Washing Icon

    Cleanse

    Delivers topical wound solutions that dwell in the wound to help dilute and solubilize infectious material³

  • Bandages Icon

    Remove

    Removes solubilized wound debris and infectious materials, under negative pressure to help lower bioburden⁴

  • Heart & Medical Cross Icon

    Promote

    Promotes granulation tissue formation and perfusion to prepare the wound for closure⁵


Bioburden formation is commonly considered to occur in five main stages.²

  • Chart showing the five main stages of Bioburden formation

Veraflo Therapy can provide positive clinical outcomes over standard of care, including traditional NPWT, in various wound types.

A systematic review of comparative studies and meta-analysis evaluated the performance of Veraflo Therapy versus control in 13 studies and 720 patients in various wound types. Results of the analysis revealed Veraflo Therapy delivered significant advantage over standard of care, including traditional NPWT.

  • Calendar Icon
    >50% reduced length of therapy⁶,⁷

    (9.88 days vs 21.8 days, p=0.02)

  • Speedometer Icon
    Ready for closure almost twice as fast

    (7.88 days vs 14.36 days, p=0.003)

  • Greater Than 2 Times Icon
    Wounds were 2.39 times more likely to close⁶,⁷

    (p=0.01)

  • Arrow pointing downards Icon
    >30% Fewer surgical debridements⁶,⁷

    (1.77 debridements vs 2.69, p=0.008)

  • Bacteria Icon
    Reduced bacterial count from baseline⁶

    Odds were 4.4 times greater (p=0.003)



Use of Veraflo Therapy can potentially reduce costs versus standard of care

Based upon the meta-analysis by Allen Gabriel, MD et al. an economic model⁶ was developed to compare the cost of using Veraflo Therapy to traditional wound care options including V.A.C.® Therapy. Despite higher therapy cost of Veraflo Therapy, the reduction in therapy time and required OR visits resulted in a potential savings of 50%, or up to $33,337 per patient.

NOTE: The model uses select study data to provide an illustration of estimates of costs for use of Veraflo Therapy or Standard of Care (Control). This model is an illustration and not a guarantee of actual individual costs, savings, outcomes or results. The facility is advised to use this model as an illustration only to assist in an overall assessment of products and pricing

  • Veraflo Therapy Sample Health Economic Table

Kim PJ, Lookess S, Bongards C, Griffin LP, Gabriel A. Economic model to estimate cost of negative pressure wound therapy with instillation vs control therapies for hospitalised patients in the United States, Germany, and United Kingdom. Int Wound J. 2021;1–7.



Practice efficient medicine with a smarter way to manage wounds​

Wounds may be susceptible to contamination or the development of bioburden – key contributors to complications like infection, inflammation, and delayed healing. 3M™ Veraflo™ Therapy combines vacuum assisted drainage with automated topical wound solution distribution to consistently cleanse and remove wound debris helping to reduce bioburden.


Treatment of soft tissue defect from transfemoral amputation using  3M™ Veraflo™ Therapy

Following a boating injury, a 26-year-old female received transfemoral amputation that resulted in soft tissue defect measuring approximately 90x45cm². Antibiotics were administered throughout the patient treatment period. With patient critical condition and debridement no longer an option, Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing was initiated. Dwell time: 5 minutes NPWT time: 2 hours at -150mmHg Solution: 100mL Dankin's Solution.

Patient data and photos courtesy of Brandon Hill, RN, CWCN, FACCWS; Ochsner Louisiana State University Health Shreveport, Shreveport, LA
NOTE: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient’s circumstances and condition.



Help manage various wound types including:

  • Pressure ulcer on foot
    Pressure Ulcers
  • Diabetic foot infection with ulceration
    Diabetic Wounds
  • Traumatic wound on ankle
    Traumatic Wounds
  • Surgical wound on leg
    Dehisced Wounds

3M™ Veraflo™ Therapy can be used to help promote wound healing in wounds with the following characteristics:
 

  • Clean wounds
  • Contaminated or chronically infected wounds that require cleansing​
  • Wounds with heavy bioburden​
  • Wounds that are difficult to granulate​
  • Adequately cleansed and debrided wounds


Video Resources


  • All fields are required unless indicated optional

  • 3M takes your privacy seriously. 3M and its authorized third parties will use the information you provided in accordance with our Privacy Policy to send you communications which may include promotions, product information and service offers. Please be aware that this information may be stored on a server located in the U.S. If you do not consent to this use of your personal information, please do not use this system.

  • Submit

Our apologies...

An error has occurred while submitting. Please try again later...

Thank you!

Your form was submitted successfully. A 3M representative will reach out to you soon.


Interested in learning more about Veraflo Therapy?

From product demos, purchase inquiries to technical training, our team is here to help.



View all related products


1. Bjarnsholt T, Eberlein T, Malone M, Schultz G. Management of wound biofilm made easy. London: Wounds International 2017; 8(2).
2. A fact a day – biofilms and wound care. Wound Source. 2018. Available at: https://pages.woundsource.com/woundsource-practice-accelerator-biofilms-and-wound-care/.
3. Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate, Int Wound J. 2017 Oct;14(5):842-848.
4. Brinkert D, Mazen A, Naud M, Maire N, Trial C, Teot L. Negative pressure wound therapy with saline instillation: 131 patient case series. Int Wound J. 2013 Dec;10 Suppl1:56-60.
5. Gupta S, Gabriel A, Lantis J, Teot L. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. Int Wound J. 2016 Apr; 13(2):159-174.
6. Gabriel, Allen MD, FACS; Camardo, Mark MS; O’Rorke, Erin BS; Gold, Rebecca BS; Kim, Paul J.DPM, MS, FACFAS Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis, Plastic and Reconstructive Surgery: January 2021 - Volume 147 - Issue1S-1 - p 68S-76S doi:10.1097/PRS.0000000000007614.
7. Camardo, Mark. “Veraflo Meta-Analysis Standardized and Non-Standardized Means.”, 3M Internal Report, San Antonio,Texas, 2020.
Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. J Wound Care. 2010; 19 (8):320-328.
8. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infection. Science. 1999; 284 (5418):1318-1322.
9. Davies DG, Geesey GG. Regulation of the Alginate Biosynthesis Gene algC in Pseudomonas aeruginosa during Biofilm Development in Continuous Culture. Appl Environ Microbiol. 1995; 61(3):860-867.
10. Cicmanec F, Holder IA. Growth of Pseudomonas aeruginosa in Normal and Burned Skin Extract: Role of Extracellular Proteases. Infect Immun. 1979; 25(2):477-483.
11. Harrison-Balestra C, Cazzaniga BS, Davis SC, et al. A Wound-Isolated Pseudomonas aeruginosa Grows a Biofilm In Vitro Within 10 Hours and Is Visualized by Light Microscopy. Dermatol Surg. 2003: 29(6):631-635.
12. Schaber JA, Triffo WJ, Suh SJ, et al. Pseudomonas aeruginosa Forms Biofilms in Acute Infection Independent of Cell-to-Cell Signaling. Infect Immun. 2007; 75 (8):3715-3721.
13. Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. J Wound Care. 2010; 19 (8):320-328.
14. Kim PJ, Attinger CE, Constantine T, et al. Negative pressure wound therapy with instillation: international consensus guidelines update. Int Wound J. 2020 Feb;17(1):174-186